{"id":"docetaxel-xrp6976-modafinil","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Headache (modafinil-related)"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1672355","moleculeType":"Small molecule","molecularWeight":"273.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Modafinil is a wakefulness-promoting agent that acts on multiple neurotransmitter systems (dopamine, norepinephrine, histamine) to combat chemotherapy-induced fatigue and cognitive impairment, potentially improving patient compliance and quality of life during treatment.","oneSentence":"Docetaxel stabilizes microtubules to inhibit cancer cell division, while modafinil enhances wakefulness and may improve treatment tolerability and cognitive function during chemotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:41.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 investigational)"},{"name":"Cancer-related fatigue and cognitive impairment during chemotherapy"}]},"trialDetails":[{"nctId":"NCT00917748","phase":"PHASE3","title":"Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Prostatic Neoplasms, Breast Cancer","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DOCETAXEL(XRP6976) + MODAFINIL","genericName":"DOCETAXEL(XRP6976) + MODAFINIL","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel stabilizes microtubules to inhibit cancer cell division, while modafinil enhances wakefulness and may improve treatment tolerability and cognitive function during chemotherapy. Used for Advanced or metastatic solid tumors (Phase 3 investigational), Cancer-related fatigue and cognitive impairment during chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}